Taysha Gene Therapies Inc (NASDAQ:TSHA) shares, rose in value on Tuesday, December 31, without any change to the previous day’s close as strong demand from buyers drove the stock to $1.73.
Actively observing the price movement in the last trading, the stock closed the session at $1.73, falling within a range of $1.66 and $1.79. Referring to stock’s 52-week performance, its high was $4.32, and the low was $1.19. On the whole, TSHA has fluctuated by -46.60% over the past month.
With the market capitalization of Taysha Gene Therapies Inc currently standing at about $354.55 million, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 2.05M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TSHA’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of TSHA currently trading nearly -17.77% and -17.32% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.74, while the 7-day volatility ratio is showing 7.19% which for the 30-day chart, stands at 9.26%. Furthermore, Taysha Gene Therapies Inc (TSHA)’s beta value is 0.91, and its average true range (ATR) is 0.19.
A comparison of Taysha Gene Therapies Inc (TSHA) with its peers suggests the former has fared considerably weaker in the market. TSHA showed an intraday change of 0.00% in last session, and over the past year, it shrunk by -2.26%%.
Data on historical trading for Taysha Gene Therapies Inc (NASDAQ:TSHA) indicates that the trading volumes over the past 10 days have averaged 2.4 and over the past 3 months, they’ve averaged 4.32 million. According to company’s latest data on outstanding shares, there are 204.94 million shares outstanding.
Nearly 25.05% of Taysha Gene Therapies Inc’s shares belong to company insiders and institutional investors own 69.54% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 21.88 million shares as on 2024-12-13, resulting in a short ratio of 3.66. According to the data, the short interest in Taysha Gene Therapies Inc (TSHA) stood at 1409.00 of shares outstanding as of 2024-12-13; the number of short shares registered in 2024-11-15 reached 15.75 million. The stock has fallen by -2.26% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TSHA stock heading into the next quarter.
